WO2001000197A2 - Methods of treating fungal infections with inhibitors of nad synthetase enzyme - Google Patents

Methods of treating fungal infections with inhibitors of nad synthetase enzyme Download PDF

Info

Publication number
WO2001000197A2
WO2001000197A2 PCT/US2000/018029 US0018029W WO0100197A2 WO 2001000197 A2 WO2001000197 A2 WO 2001000197A2 US 0018029 W US0018029 W US 0018029W WO 0100197 A2 WO0100197 A2 WO 0100197A2
Authority
WO
WIPO (PCT)
Prior art keywords
integer
och
compound
compounds
compound administered
Prior art date
Application number
PCT/US2000/018029
Other languages
English (en)
French (fr)
Other versions
WO2001000197A3 (en
Inventor
Wayne J. Brouillette
Christie G. Brouillette
Lawrence J. Delucas
Original Assignee
The Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Uab Research Foundation filed Critical The Uab Research Foundation
Priority to IL14728100A priority Critical patent/IL147281A0/xx
Priority to CA002376892A priority patent/CA2376892A1/en
Priority to JP2001505907A priority patent/JP2003503347A/ja
Priority to EP00943322A priority patent/EP1194135A2/de
Priority to AU57808/00A priority patent/AU5780800A/en
Priority to BR0012135-5A priority patent/BR0012135A/pt
Publication of WO2001000197A2 publication Critical patent/WO2001000197A2/en
Publication of WO2001000197A3 publication Critical patent/WO2001000197A3/en
Priority to US10/080,279 priority patent/US6861448B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PCT/US2000/018029 1998-01-14 2000-06-29 Methods of treating fungal infections with inhibitors of nad synthetase enzyme WO2001000197A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IL14728100A IL147281A0 (en) 1999-06-29 2000-06-29 Methods of treating fungal infections with inhibitors of nad synthetase enzyme
CA002376892A CA2376892A1 (en) 1999-06-29 2000-06-29 Methods of treating fungal infections with inhibitors of nad synthetase enzyme
JP2001505907A JP2003503347A (ja) 1999-06-29 2000-06-29 Ｎａｄシンテターゼ酵素のインヒビターを用いた真菌感染の治療法
EP00943322A EP1194135A2 (de) 1999-06-29 2000-06-29 Verfahren zur behandlung von pilzinfektionen mit hemmern des nad synthetase enzyms
AU57808/00A AU5780800A (en) 1999-06-29 2000-06-29 Methods of treating fungal infections with inhibitors of nad synthetase enzyme
BR0012135-5A BR0012135A (pt) 1999-06-29 2000-06-29 Métodos de tratamento de infecções de fungos com inibidores de enzima sintetase nad
US10/080,279 US6861448B2 (en) 1998-01-14 2002-02-22 NAD synthetase inhibitors and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14143699P 1999-06-29 1999-06-29
US60/141,436 1999-06-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022203 Continuation-In-Part WO2002007516A2 (en) 1998-01-14 2001-07-13 Uses for nad synthetase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/080,279 Continuation-In-Part US6861448B2 (en) 1998-01-14 2002-02-22 NAD synthetase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
WO2001000197A2 true WO2001000197A2 (en) 2001-01-04
WO2001000197A3 WO2001000197A3 (en) 2001-09-07

Family

ID=22495679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/018029 WO2001000197A2 (en) 1998-01-14 2000-06-29 Methods of treating fungal infections with inhibitors of nad synthetase enzyme

Country Status (7)

Country Link
EP (1) EP1194135A2 (de)
JP (1) JP2003503347A (de)
AU (1) AU5780800A (de)
BR (1) BR0012135A (de)
CA (1) CA2376892A1 (de)
IL (1) IL147281A0 (de)
WO (1) WO2001000197A2 (de)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007516A2 (en) * 2000-07-14 2002-01-31 The Uab Research Foundation Uses for nad synthetase inhibitors
US7705023B2 (en) 2004-06-18 2010-04-27 Biolipox Ab Indoles useful in the treatment of inflammation
WO2011089576A3 (en) * 2010-01-25 2011-11-03 Kareus Therapeuttics Sa Novel compositions for reducing abeta 42 production and their use in treating alzheimer's disease (ad)
US8097623B2 (en) 2005-01-19 2012-01-17 Biolipox Ab Indoles useful in the treatment of inflammation
US8993560B2 (en) 2011-03-11 2015-03-31 Glaxo Group Limited Compounds
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
US11767337B2 (en) 2020-02-18 2023-09-26 Gilead Sciences, Inc. Antiviral compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036422A1 (en) * 1998-01-14 1999-07-22 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
WO2000010996A1 (en) * 1998-08-25 2000-03-02 The Uab Research Foundation Inhibitors of bacterial nad synthetase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036422A1 (en) * 1998-01-14 1999-07-22 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
WO2000010996A1 (en) * 1998-08-25 2000-03-02 The Uab Research Foundation Inhibitors of bacterial nad synthetase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D.R. SHRIDHAR ET AL.: "Antimicrobial Agents: Synthesis and Antimicrobial Activity of New Aryloxyalkyl Esters of p-Hydroxybenzoic acid" JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 65, no. 7, 1976, pages 1074-1078, XP002159389 *
D.R. SHRIDHAR ET AL.: "Antimicrobial Agents-Part III" J. INDIAN CHEM SOC., vol. LVI, 1979, pages 74-76, XP000979792 *
SCHMITT L J (REPRINT) ET AL: "The synthesis of tethered heterocyclic dimers as inhibitors of NAD synthetase." ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, (23 AUG 1998) VOL. 216, PART 2, PP. 247-MEDI. PUBLISHER: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036. ISSN: 0065-7727., XP000981301 UNIV ALABAMA, CTR MACROMOL CRYSTALLOG, BIRMINGHAM, AL 35294;UNIV ALABAMA, DEPT CHEM, BIRMINGHAM, AL 35294 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007516A2 (en) * 2000-07-14 2002-01-31 The Uab Research Foundation Uses for nad synthetase inhibitors
WO2002007516A3 (en) * 2000-07-14 2002-06-27 Uab Research Foundation Uses for nad synthetase inhibitors
US7705023B2 (en) 2004-06-18 2010-04-27 Biolipox Ab Indoles useful in the treatment of inflammation
US8097623B2 (en) 2005-01-19 2012-01-17 Biolipox Ab Indoles useful in the treatment of inflammation
WO2011089576A3 (en) * 2010-01-25 2011-11-03 Kareus Therapeuttics Sa Novel compositions for reducing abeta 42 production and their use in treating alzheimer's disease (ad)
CN102712595A (zh) * 2010-01-25 2012-10-03 凯瑞斯治疗公司 用于减少Aβ42的产生的新型化合物及其在治疗阿尔茨海默病（AD）中的应用
JP2013533843A (ja) * 2010-01-25 2013-08-29 カレウス セラピューティクス エスエー Ａβ４２の生成を減少させる新規な組成物及びアルツハイマー病（ＡＤ）の治療におけるその使用
US8993560B2 (en) 2011-03-11 2015-03-31 Glaxo Group Limited Compounds
US9447074B2 (en) 2011-03-11 2016-09-20 Glaxo Group Limited Compounds
US11767337B2 (en) 2020-02-18 2023-09-26 Gilead Sciences, Inc. Antiviral compounds
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides

Also Published As

Publication number Publication date
AU5780800A (en) 2001-01-31
WO2001000197A3 (en) 2001-09-07
BR0012135A (pt) 2002-07-02
IL147281A0 (en) 2002-08-14
JP2003503347A (ja) 2003-01-28
EP1194135A2 (de) 2002-04-10
CA2376892A1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
CA1321748C (en) Antifungal compositions and method of controlling myotic infections
US6500852B1 (en) Inhibitors of bacterial NAD synthetase
EP1963258A2 (de) Histon-deacetylase-hemmer zur verstärkung der aktivität antifungaler wirkstoffe
US6861448B2 (en) NAD synthetase inhibitors and uses thereof
JP2011507822A (ja) 抗菌性化合物
JP2005509594A (ja) Ｎａｄシンテターゼ阻害剤およびその使用
US4920112A (en) Fungicidal compositions and method
WO2012137224A1 (en) Coumarin compounds for the treatment of mycobacterial infections
CN107980000A (zh) 包含抗菌剂的药物组合物
WO2001000197A2 (en) Methods of treating fungal infections with inhibitors of nad synthetase enzyme
US6673827B1 (en) Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
WO2021006317A1 (ja) プロトテカ症の新規治療剤
EP3037412B1 (de) Indolamidverbindung als nekrosehemmer
EP2077260B1 (de) Amidverbindung oder salz davon und inhibitor der bildung von biologischen filmen, substanz zum entfernen biologischer filme und bakterizid, bei denen jeweils die amidverbindung oder ein salz davon verwendet wird
KR102358632B1 (ko) 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물
US20220281803A1 (en) Molecular design of new antibiotics and antibiotic adjuvants against mcr strains
US4920111A (en) Fungicidal compositions and methods utilizing 25-azasterol and HMG-CoA reductase inhibitors
US4920113A (en) Fungicidal compositions and methods utilizing 25-azasterol and HMG-CoA synthase inhibitors
EP2548865B1 (de) Neue Neue Bis-Indol-Derivate, deren Verwendung speziell als antibakterielles Mittel
US20030171379A1 (en) Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds
KR100854309B1 (ko) 항미코박테리아성 약제학적 조성물
CA2415900A1 (en) Uses for nad synthetase inhibitors
CA2447470A1 (en) Peptide deformylase activated prodrugs
WO2020141478A1 (en) Thiazolyl peptides for the treatment nontuberculous mycobacterial infections
EP3612512A1 (de) Antimikrobielle wirkstoffe

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2376892

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 57808/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000943322

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000943322

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000943322

Country of ref document: EP